# A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Allogenic Hematopoietic Cell Transplantation (HCT) Participants.

> **NCT05683457** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **ModernaTX, Inc.** · enrollment: 84 (actual)

## Conditions studied

- Cytomegalovirus Infection

## Interventions

- **BIOLOGICAL:** mRNA-1647
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT05683457
- **Lead sponsor:** ModernaTX, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-04-05
- **Primary completion:** 2026-08-01
- **Final completion:** 2026-08-01
- **Target enrollment:** 84 (ACTUAL)
- **Last updated:** 2026-05-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05683457

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05683457, "A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Allogenic Hematopoietic Cell Transplantation (HCT) Participants.". Retrieved via AI Analytics 2026-08-22 from https://api.ai-analytics.org/clinical/NCT05683457. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*